Fulgent Genetics Inc reports results for the quarter ended September 30 - Earnings Summary

• Fulgent Genetics Inc FLGT.OQ reported quarterly adjusted earnings of 31 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -39 cents. The mean expectation of three analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -19 cents to -9 cents per share.

• Revenue fell 15.3% to $71.74 million from a year ago; analysts expected $71.72 million.

• Fulgent Genetics Inc's reported EPS for the quarter was a loss of 48 cents​.

• The company reported a quarterly loss of $14.65 million.

• Fulgent Genetics Inc shares had risen by 1.3% this quarter and lost 23.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the healthcare facilities & services peer group is also "hold"

Wall Street's median 12-month price target for Fulgent Genetics Inc is 27.00

This summary was machine generated from LSEG data November 8 at 04:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)